Atsunori Kashiwagi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5291009/publications.pdf

Version: 2024-02-01

37 papers	1,919 citations	361413 20 h-index	315739 38 g-index
40 all docs	40 docs citations	40 times ranked	2161 citing authors

#	Article	IF	Citations
1	International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Journal of Diabetes Investigation, 2012, 3, 39-40.	2.4	731
2	Randomized, placeboâ€controlled, doubleâ€blind glycemic control trial of novel sodiumâ€dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2014, 5, 382-391.	2.4	90
3	Omega-3 polyunsaturated fatty acid has an anti-oxidant effect via the Nrf-2/HO-1 pathway in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications, 2013, 430, 225-230.	2.1	81
4	Glucose area under the curve during oral glucose tolerance test as an index of glucose intolerance. Diabetology International, 2016, 7, 53-58.	1.4	81
5	4-Hydroxy Hexenal Derived from Docosahexaenoic Acid Protects Endothelial Cells via Nrf2 Activation. PLoS ONE, 2013, 8, e69415.	2.5	69
6	Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. Journal of the American College of Cardiology, 2001, 38, 1821-1828.	2.8	68
7	Ipragliflozin improves glycemic control in Japanese patients with type 2 diabetes mellitus: the BRIGHTEN study. Diabetology International, 2015, 6, 8-18.	1.4	66
8	Low concentration of 4-hydroxy hexenal increases heme oxygenase-1 expression through activation of Nrf2 and antioxidative activity in vascular endothelial cells. Biochemical and Biophysical Research Communications, 2010, 402, 99-104.	2.1	65
9	Metabolic and hemodynamic effects of sodiumâ€dependent glucose cotransporter 2 inhibitors on cardioâ€renal protection in the treatment of patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2017, 8, 416-427.	2.4	59
10	Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin resistance state. Diabetes Research and Clinical Practice, 1999, 45, 199-203.	2.8	49
11	Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis, 2016, 246, 141-147.	0.8	48
12	Efficacy and safety of ipragliflozin as an add-on to a sulfonylurea in Japanese patients with inadequately controlled type 2 diabetes: results of the randomized, placebo-controlled, double-blind, phase III EMIT study. Diabetology International, 2015, 6, 125-138.	1.4	47
13	Efficacy and safety of ipragliflozin as an add-on to pioglitazone in Japanese patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study (the SPOTLIGHT) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	47
14	A fish-based diet intervention improves endothelial function in postmenopausal women with type 2 diabetes mellitus: A randomized crossover trial. Metabolism: Clinical and Experimental, 2014, 63, 930-940.	3.4	43
15	Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care, 2018, 41, 1275-1284.	8.6	43
16	Definitive diagnosis of mandibular hypoplasia, deafness, progeroid features and lipodystrophy (MDPL) syndrome caused by a recurrent <i>de novo</i> mutation in the <i>POLD1</i> gene. Endocrine Journal, 2018, 65, 227-238.	1.6	42
17	Insulin Signaling and Its Regulation of System A Amino Acid Uptake in Cultured Rat Vascular Smooth Muscle Cells. Circulation Research, 1996, 79, 1167-1176.	4.5	33
18	Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. Diabetes Research and Clinical Practice, 2014, 106, 50-56.	2.8	32

#	Article	IF	Citations
19	Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials. Journal of Diabetes Investigation, 2016, 7, 544-554.	2.4	29
20	Efficacy and safety of 40Âmg or 60Âmg duloxetine in J apanese adults with diabetic neuropathic pain: Results from a randomized, 52â€week, openâ€label study. Journal of Diabetes Investigation, 2016, 7, 100-108.	2.4	23
21	Porphyromonas gingivalis induces entero-hepatic metabolic derangements with alteration of gut microbiota in a type 2 diabetes mouse model. Scientific Reports, 2021, 11, 18398.	3.3	19
22	Sodiumâ€“glucose cotransporterÂ2 inhibitors represent a paradigm shift in the prevention of heart failure in typeÂ2 diabetes patients. Journal of Diabetes Investigation, 2021, 12, 6-20.	2.4	17
23	Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). Journal of Diabetes Investigation, 2016, 7, 386-395.	2.4	15
24	Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials. Endocrine Journal, 2018, 65, 693-705.	1.6	15
25	Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study. Diabetes, Obesity and Metabolism, 2019, 21, 791-800.	4.4	15
26	Comparison of clinical characteristics in patients with typeÂ2 diabetes among whom different antihyperglycemic agents were prescribed as monotherapy or combination therapy by diabetes specialists. Journal of Diabetes Investigation, 2016, 7, 260-269.	2.4	13
27	Effects of ipragliflozin, a selective sodiumâ€“glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. Diabetology International, 2017, 8, 76-86.	1.4	12
28	Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial. PLoS ONE, 2016, 11, e0164936.	2.5	11
29	Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Therapy, 2019, 10, 2201-2217.	2.5	11
30	Impact of obesity on annual medical expenditures and diabetes care in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2018, 9, 776-781.	2.4	10
31	Duality of n-3 Polyunsaturated Fatty Acids on Mcp-1 Expression in Vascular Smooth Muscle: A Potential Role of 4-Hydroxy Hexenal. Nutrients, 2015, 7, 8112-8126.	4.1	7
32	Evaluation of a Novel Glucose Area Under the Curve (AUC) Monitoring System: Comparison with the AUC by Continuous Glucose Monitoring. Diabetes and Metabolism Journal, 2016, 40, 326.	4.7	7
33	Liraglutide versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33). Japanese Clinical Medicine, 2014, 5, JCM.S16585.	1.9	6
34	Preserving Î²-cell function is the major determinant of diabetes remission following laparoscopic sleeve gastrectomy in Japanese obese diabetic patients. Endocrine Journal, 2019, 66, 817-826.	1.6	6
35	Reduction in cardiovascular disease events in patients with typeâ€‰2 diabetes mellitus treated with a sodiumâ€“glucose cotransporterâ€‰2 inhibitor versus a dipeptidyl peptidaseâ€4 inhibitor: A realâ€world retrospective administrative database analysis in Japan. Journal of Diabetes Investigation, 2022, 13, 1175-1189.	2.4	5
36	A new door opens, but it is essential to accumulate further clinical evidence to control heart failure in diabetes with preserved ejection fraction. Journal of Diabetes Investigation, 2019, 10, 1145-1147.	2.4	2

#	Article	IF	Citations
37	A Prospective, Open-Label Short-Term Pilot Study on Modification of the Skin Hydration Status During Treatment With a Sodium-Glucose Cotransporter-2 Inhibitor. Diabetes Therapy, 2021, 12, 431-440.	2.5	2